Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
18 March 2021 | Story Leonie Bolleurs
Famelab
Abdullahi Jamiu, who is working on his master's degree in Microbiology, was adjudicated as the FameLab winner at the Central Regional Heat and will represent the region at the national semi-finals.

Abdullahi Jamiu, who is working on his master's degree in Microbiology in the Department of Microbiology and Biochemistry at the University of the Free State (UFS), was recently announced as the FameLab winner at the Central Regional Heat and will represent the region at the national semi-finals.

Abdullahi, who plans on pursuing a doctoral degree after his master’s, says he wants to establish himself as an academic in microbiology.

Making science simple
He says he decided to participate in the FameLab competition because he is very passionate about communicating science. “Science communication affords me the opportunity to not only take my research outside of the lab space, but also to communicate it to the lay audience. Moreover, science is often perceived by the general public as difficult and unfathomable. As such, science communication programmes promote the simplification and better understanding of scientific knowledge in the community,” he says.

FameLab is coordinated by the South African Agency for Science and Technology Advancement, the British Council, and Jive Media Africa.

According to Abdullahi, the experience was mind-blowing. “It gave me the opportunity to compress my 200-page master's thesis into a three-minute talk in a way I had never thought was possible. Having to present virtually and adjust to the ‘new normal’ was quite challenging,” he adds.

“The overall experience was enlightening and engaging, and at the same time entertaining,” says Abdullahi.

Impressing the judges with his charisma, engagement with the audience, and use of props, Abdullahi’s presentation focused on how the exploration and exploitation of a ‘combination therapy’ approach to drug discovery could help to effectively combat fungal infections, which are the common comorbidities in immune-compromised individuals, including those living with HIV, cancer, and COVID-19.

Revealing an enigma
His fascination with microbiology started at a young age. “How very tiny, microscopic creatures, invisible to the unaided eye, are able to infect and sometimes kill both healthy and immune-compromised individuals, was an enigma to me as a little boy. My desire to unravel this mystery triggered my interest in microbiology, and the more I learn, the more enthusiastic I become to broaden my horizon in this challenging yet exciting field of study,” he says.

Abdullahi would like to one day make a difference by conducting relevant research aimed at contributing to finding lasting solutions to the lingering menace posed by pathogenic microbes. “Moreover, I am very passionate about facilitating the transfer of scientific knowledge to the next generation,” Abdullahi concludes.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept